Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hedan Tablets in Nonalcoholic Simple Fatty Liver Disease
CTR20131131Phase 2Active
- Start
- Nov 2013
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Hedan Tablets with Placebo (2 arms). Primary endpoint: Liver/spleen CT ratio. Started Nov 2013; status: active.
02
Drugs
Hedan Tablets
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on CTR20131131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131131.